Get the Stockscreener App
1.82
7.61%
-0.15
After Hours:
1.83
0.01
+0.55%
Alx Oncology Holdings Inc stock is traded at $1.82, with a volume of 605.83K.
It is down -7.61% in the last 24 hours and down -21.55% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.97
Open:
$1.96
24h Volume:
605.83K
Relative Volume:
0.51
Market Cap:
$94.81M
Revenue:
-
Net Income/Loss:
$-160.81M
P/E Ratio:
-0.5688
EPS:
-3.2
Net Cash Flow:
$-131.64M
1W Performance:
-8.54%
1M Performance:
-21.55%
6M Performance:
-83.68%
1Y Performance:
-62.08%
1-Day Range:
$1.77
$1.99
1-Week Range:
$1.76
$2.06
52-Week Range:
$1.76
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
A Guide To The Risks Of Investing In Alx Oncology Holdings Inc (ALXO) - Knox Daily
Market Recap Check: Alx Oncology Holdings Inc (ALXO)’s Positive Finish at 1.97, Up/Down 5.35 - The Dwinnex
Susquehanna Portfolio Strategies LLC Sells 17,489 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com India
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Bank of New York Mellon Corp Acquires 25,199 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Inspire Investing LLC Has $354,000 Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ACLX, HROW Deliver Triple-Digit ReturnsDid You Cash In? - RTTNews
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Up 7.5% in August - Defense World
Alignment Healthcare (NASDAQ:ALHC) Sees Strong Trading Volume - Defense World
This $6.5 billion ASX 200 share just crashed 12%! - The Motley Fool Australia
Australia's ALS tumbles on subdued half-year forecast - XM
ALS Limited Reports Mixed Half-Year Trading Results - TipRanks
Market cap of Allarity Therapeutics Inc [ALLR] reaches 4.22M – now what? - The DBT News
Alclear Investments II sells $3.8 million in Clear Secure stock By Investing.com - Investing.com UK
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Arcellx Sees Unusually Large Options Volume (NASDAQ:ACLX) - Defense World
Alexander's (NYSE:ALX) Hits New 52-Week High at $248.10 - MarketBeat
Allogene Therapeutics Inc (ALLO) is looking forward to a strong quarter - SETE News
Ratio Examination: Alcon Inc. (ALC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Allarity Therapeutics Inc (ALLR) can make a big difference with a little luck - SETE News
Financial Analysis: Allogene Therapeutics Inc (ALLO)’s Ratios Unveil Key Insights - The Dwinnex
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ForexTV.com
Arcellx CFO Michelle Gilson sells shares worth over $1.1 million - Investing.com
ALLARITY ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
(ALX) Proactive Strategies - Stock Traders Daily
When (ALNY) Moves Investors should Listen - Stock Traders Daily
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Allarity Therapeutics, Inc. (ALLR) Investors - Business Wire
Where are the Opportunities in (ACLX) - Stock Traders Daily
Dai ichi Life Insurance Company Ltd Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Investing in Allarity Therapeutics Inc (ALLR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Increase in Short Interest - MarketBeat
AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC - Defense World
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Allarity Therapeutics, Inc. - GlobeNewswire
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Looking Into Allarity Therapeutics's Recent Short Interest - Benzinga
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - ForexTV.com
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
TD Cowen maintains Alnylam stock at Buy rating with steady price target - Investing.com India
Allogene Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Allogene Therapeutics Inc (ALLO) deserves closer scrutiny - US Post News
Ratio Revelations: Allarity Therapeutics Inc (ALLR)’s Financial Metrics in the Spotlight - The Dwinnex
Short Interest in Alpha and Omega Semiconductor Limited (NASDAQ:AOSL) Grows By 22.6% - MarketBeat
Forsta AP Fonden Has $6.12 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):